Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

ELC Group Announces Appointment of Dr. Siddharth Chachad

Published: Thursday, August 21, 2014
Last Updated: Thursday, August 21, 2014
Bookmark and Share
Internationally acclaimed clinical pharmacologist joins global regulatory affairs specialist in key management post.

ELC Group has announced the appointment of internationally acclaimed clinical pharmacologist Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs.

A member of the UK Faculty of Pharmaceutical Medicine, Dr. Chachad is an expert in the design and execution of pre-clinical and clinical development programme for drug products across dosage forms and therapeutic categories. Dr. Chachad has gained considerable career experience in the delivery medical services, medico-regulatory affairs and clinical development, and has worked across global clinical development strategy and operations of generics, new drugs and biosimilars. Dr. Siddharth’s extensive expertise covers all phases of clinical studies, including pre-clinical, pharmacodynamic studies, bioequivalence, PK in patients and full-blown clinical efficacy and safety studies.

“The appointment of Dr. Siddharth Chachad comes at a pivotal time for ELC Group,” said Marco Rubenstein, CEO of ELC Group. “Having been instrumental in the development of successful product registration strategies, I have no doubt that Dr. Siddarth will prove an exceptional leader of our Global Clinical Development and Medical Affairs team.”

Dr. Chachad added: “I am excited to be joining ELC Group and bringing my experience of Clinical Development and Medical Affairs to what is already a world-class team in this area.”

A renowned speaker at numerous clinical research and pharmacovigilance conferences, Dr. Chachad has authored over 25 publications.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ELC Group Expands into Pharmaceutical Product Development Market
Fast-growing regulatory affairs provider creating extensive product portfolio for sale across US, EU, LATAM, MENA and China.
Saturday, June 13, 2015
ELC Group Signs 1.5 Million Euro Regulatory Affairs Contract
Landmark deal ELC Group’s Concept to Commercialization solution approach.
Friday, May 01, 2015
ELC Group Appoints Head of Regulatory Affairs for Russia and CIS
Inna Demidova to head new Moscow office for fast-growing global regulatory affairs specialist.
Tuesday, July 29, 2014
ELC Group Launches Clinical Trials Services
ELC Group now offering comprehensive range of consultancy and support services for clinical trials.
Thursday, February 21, 2013
ELC GROUP Aim to Foster Strategic and Economic Ties Within India and China
Company visit to addresses regulatory challenges for 2012.
Wednesday, July 13, 2011
ELC Group Announces Doubled Revenues
Company set to increase expansion through acquisition.
Thursday, May 26, 2011
ELC GROUP Appoints Former TOPRA President
World-renowned physician Dr. Paolo Biffignandi joins ELC GROUP’s Advisory Board.
Friday, May 13, 2011
Scientific News
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Electronic Reminders Keep TB Patients on Track With Medication In China
Giving electronic reminders to tuberculosis (TB) patients in China can reduce the amount of medication doses they miss by half, according to new research.
Common Drug Presents Fracture Risk To Older Women
Researchers are urging caution in prescribing one of the world’s most commonly issued drug groups, citing links to increased fracture risks in older Australian women.
Combining Epigenetic Therapies and Immunotherapies Improves Cancer Outcomes
Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs.
LiMAx Test Shows Reversibility of Fatty Liver Disease After Obesity Surgery
Clinical study provides evidence for functional liver recovery after weight loss.
Landmark NIH Study Shows Intensive Blood Pressure Management May Save Lives
Lower blood pressure target greatly reduces cardiovascular complications and deaths in older adults.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos